Physician profile
Farrukh Munir
NPI 1720430648
$2,635.95
in general payments reported to CMS, 2019-2025
32 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $214 · 2024: $660 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.96 |
| Education | $268.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $353.10 | 2024-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $309.93 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $309.59 | 2024-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $199.86 | 2023-2025 | Breyanzi, Opdivo |
| Janssen Biotech, INC. | $184.53 | 2024-2025 | Darzalex, Talvey, Rybrevant |
| Abbvie INC. | $152.10 | 2024-2025 | |
| Astellas Pharma US INC | $132.14 | 2024-2025 | Vyloy, Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2023 | Imbruvica |
| Glaxosmithkline, LLC. | $89.58 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Merck Sharp & Dohme LLC | $85.35 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Stemline Therapeutics INC. | $62.00 | 2024-2025 | Orserdu |
| Beone Medicines USA, INC. | $53.41 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $52.64 | 2024 | Ultomiris |
| Pfizer INC. | $49.21 | 2025 | |
| Genzyme Corporation | $48.64 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.42 | 2025 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $40.11 | 2025 | Lynozyfic, Libtayo |
| Geron Corporation | $38.12 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $36.12 | 2024-2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $34.80 | 2023-2024 | |
| Celgene Corporation | $32.71 | 2025 | Reblozyl, Breyanzi |
| Incyte Corporation | $31.12 | 2025 | Zynyz, Monjuvi |
| Seagen INC. | $27.90 | 2023 | Tukysa, Adcetris |
| Apellis Pharmaceuticals, INC. | $23.87 | 2025 | |
| Emd Serono, INC. | $21.73 | 2025 | |
| Progenics Pharmaceuticals, INC. | $21.06 | 2024 | |
| Secura Bio, INC. | $18.46 | 2024 | Copiktra |
| Eisai INC. | $18.39 | 2024 | |
| Beigene USA, INC. | $17.79 | 2025 | Tevimbra |
| Genentech USA, INC. | $17.09 | 2024 | Phesgo |
| Agios Pharmaceuticals, INC. | $16.40 | 2024 | Pyrukynd |
| Sobi, INC | $13.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrukh Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.